ENSG00000237434 and proximal spinal muscular atrophy: When combining the evidence from the above-mentioned studies, it becomes clear that SMN-P has the potential to serve as a diagnostic and prognostic biomarker in SMA, but that its ability to reflect dynamic processes such as disease progression or therapeutic response is still limited.